Eli Lilly and Company LLY reported fourth-quarter 2025 adjusted earnings per share (“EPS”) of $7.54, which beat the Zacks Consensus Estimate of $6.99 per share. Earnings rose 42% year over year.
The US plans to slash the price it pays for Botox and diabetes drug Trulicity, the latest medicines to be targeted under legislation that’s expected to save the government more than $200 billion over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results